Non-muscle-invasive Bladder Cancer Clinical Trial
Official title:
A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non-Muscle Invasive Bladder Cancer Patients
This is a randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer
Patients will be randomized in a 1:1:1 ratio to receive treatment with Durvalumab + BCG combination therapies, or Standard of Care (SoC) therapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05483868 -
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT05547516 -
Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients
|
N/A | |
| Not yet recruiting |
NCT05580354 -
Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer
|
Phase 4 | |
| Recruiting |
NCT05519241 -
A Phase I Intravesical PPM Therapy for NMIBC
|
Phase 1 | |
| Not yet recruiting |
NCT05002556 -
AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer
|
||
| Recruiting |
NCT05544552 -
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05796375 -
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
|
N/A | |
| Recruiting |
NCT05790850 -
Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)
|
N/A | |
| Completed |
NCT03664258 -
A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)
|
||
| Not yet recruiting |
NCT05962541 -
Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)
|
Phase 4 | |
| Active, not recruiting |
NCT05864599 -
External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group
|
||
| Not yet recruiting |
NCT03950362 -
Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
| Recruiting |
NCT05710848 -
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05232136 -
OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05825950 -
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
|
||
| Recruiting |
NCT05626101 -
Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study
|
N/A | |
| Recruiting |
NCT05538663 -
Intravesical BCG vs GEMDOCE in NMIBC
|
Phase 3 | |
| Recruiting |
NCT06245759 -
The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer Patients
|
||
| Active, not recruiting |
NCT04690699 -
LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of Lerapolturev (PVSRIPO) and Lerapolturev in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT05675176 -
Antegrade Observational Comparative Study for the Intravesical Instillation Therapy of Bacillus Calmette Guerin With the Use of Different Types of Urinary Catheters in Patients With Urinary Bladder Cancer
|